Mar 18 2020 |
Court Directs FCC To Report On Pending Lucas Petition Status |
Squire Patton Boggs (US) LLP |
Mar 18 2020 |
EDNY Passes on Potatoes Lawsuit |
Proskauer Rose LLP |
Mar 18 2020 |
CCPA Compliance Update: Three Key Revisions to Regulations |
ArentFox Schiff LLP |
Mar 17 2020 |
CMS Announces COVID-19 Nursing Facility Waivers, Critical Measures to Keep Residents Safe |
Greenberg Traurig, LLP |
Mar 17 2020 |
EFSA Issues Report to Calm Fears of COVID-19 Transmission Through Food; FDA Posts a Brief Q&A With Routine Food Safety Recommendations |
Keller and Heckman LLP |
Mar 16 2020 |
Commercial Real Estate Tips of the Week: Practical Answers from Sheppard Mullin’s Coronavirus Task Force |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 16 2020 |
Better Late than Never?: Over Fifteen Years Later Court Determines TCPA Plaintiff Lacks Article III Standing |
Troutman Amin, LLP |
Mar 16 2020 |
Recommendations by the CNIL in the Context of COVID-19 |
Squire Patton Boggs (US) LLP |
Mar 16 2020 |
California AG Urges Congress Not to Preempt the CCPA |
Jackson Lewis P.C. |
Mar 16 2020 |
Whistleblowing and The Coronavirus Crisis |
Kohn, Kohn & Colapinto |
Mar 14 2020 |
California Attorney General Proposes Further Modifications to Proposed CCPA Regulations |
Squire Patton Boggs (US) LLP |
Mar 13 2020 |
Managing the Commercial Impact of the Coronavirus: Implications for the Sports & Entertainment Industry |
Foley & Lardner LLP |
Mar 13 2020 |
CFPB Proposes Adding Financial Awards to Whistleblower Program |
Kohn, Kohn & Colapinto |
Mar 13 2020 |
CCPA: More Regulatory Changes Proposed |
Mitchell Silberberg & Knupp LLP |
Mar 13 2020 |
Coronavirus Emergency Declarations Trigger Anti-Pricing Gouging Laws |
Epstein Becker & Green, P.C. |
Mar 12 2020 |
Litigation Case Claims Violation of CCPA Under Statutory Private Right of Action |
Robinson & Cole LLP |
Mar 12 2020 |
Seventh Circuit Court of Appeals Found Bristol-Myers Not Applicable to Rule 23 Class Actions |
Squire Patton Boggs (US) LLP |
Mar 12 2020 |
Privacy, HIPAA, Security and GDPR– COVID-19 Considerations |
McDermott Will & Emery |
Mar 11 2020 |
DOJ and FTC To Focus On Antitrust and Consumer Protection Violations Relating to Coronavirus |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 11 2020 |
Turn on the Camera Part One: Keeping Your Privacy Compliant Efforts Moving Forward in the Face of COVID-19 |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 11 2020 |
Looming Data Security Requirements Under the New York SHIELD Act: What Businesses Need to Know |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
Mar 11 2020 |
Managing the Commercial Impact of the Coronavirus: Implications for Health Care |
Foley & Lardner LLP |
Mar 11 2020 |
What Should I Do If My Loved One’s Nursing Home Bans Visitors Due to Coronavirus? |
Norris McLaughlin P.A. |
Mar 11 2020 |
FTC and FDA Warn Companies About Coronavirus Treatment Claims |
Keller and Heckman LLP |
Mar 11 2020 |
FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 11 2020 |
FTC and FDA Send Warning Letters to Seven Companies about Unsupported Claims that Products Can Treat or Prevent Coronavirus |
Bergeson & Campbell, P.C. |
Mar 11 2020 |
Data Breach Enforcement in the UK and in the EU: Cross-Border Issues |
Squire Patton Boggs (US) LLP |
Mar 11 2020 |
Employers: Stop, Drop, and Ensure CCPA Compliance as to Employees Residing in California |
Greenberg Traurig, LLP |
Mar 11 2020 |
FDA and FTC Issue Warning Letters to Companies Selling Fraudulent Products to Treat or Prevent COVID-19 |
Keller and Heckman LLP |
Mar 11 2020 |
This is your Digital Life (of No Consent or Control): The Australian Information Commissioner Takes Facebook to Court |
K&L Gates |
Mar 10 2020 |
FDA and FTC Warn Companies for Unauthorized Coronavirus Disease 2019 (COVID-19) Claims |
Greenberg Traurig, LLP |
Mar 10 2020 |
HHS Finalizes Joint Rules on Electronic Health Record Interoperability and Access |
Robinson & Cole LLP |
Mar 10 2020 |
Taking the Procedural Way Out: DC Circuit Dodges Substantive Question of Whether Bristol-Myers Squibb Applies to Rule 23 Class Actions |
Squire Patton Boggs (US) LLP |
Mar 10 2020 |
SCCS Guidance on Safety Assessment of Nanomaterials in Cosmetics Published in Regulatory Toxicology and Pharmacology |
Bergeson & Campbell, P.C. |
Mar 10 2020 |
Prop 65 Warnings and Acrylamide in Food – Can I Still Have My Coffee and Drink it Too? |
Sheppard, Mullin, Richter & Hampton LLP |